Nykode Therapeutics ASA

As of June 30, 2026, NYKODE THERAPEUTICS AS carries a market capitalization of 104.92M, placing it among publicly traded companies globally. Its enterprise value stands at 61.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NYKODE THERAPEUTICS AS's next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, NYKODE THERAPEUTICS AS has 326.55M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, NYKODE THERAPEUTICS AS maintains a current ratio of 11.52, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.22, indicating elevated leverage, while an interest coverage ratio of -250.25 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, NYKODE THERAPEUTICS AS posted a negative return on equity (ROE) of -25.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, NYKODE THERAPEUTICS AS recorded an income tax benefit of -1.34M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -24.29M and -22.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 14, 2026, NYKODE THERAPEUTICS AS's stock has gained approximately 117.32% over the past 52 weeks.

Over the twelve months ended June 30, 2026, NYKODE THERAPEUTICS AS generated - - in revenue and converted that into -22.95M in net income, yielding earnings per share of -0.06. EBITDA reached -25.52M, while operating income came in at -27.65M.

As of June 30, 2026, NYKODE THERAPEUTICS AS holds 44.79M in cash and equivalents against 1.79M in total debt, resulting in a net debt position of -44.79M. Total book value stands at 80.39M, with working capital of 44.01M providing operational flexibility.

NYKODE THERAPEUTICS AS produced -27.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1,000.00 in capital expenditures, free cash flow totaled -27.14M - equivalent to -0.07 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -21.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NYKODE THERAPEUTICS AS shareholders.

NYKODE THERAPEUTICS AS's most recent stock split took place on July 7, 2020 with a 1:5 split ratio.

As of June 30, 2026, NYKODE THERAPEUTICS AS has an Altman Z-Score of 10.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.